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Children, St. Louis
Bone is not cement. Not only to serve a structural role Understandably, the nosology for heritable forms of
dense bones has been essentially a clinical/radiological/but to act importantly in biochemical processes, osseous
tissue is alive and complex and consists of a mineral genetic construct (Frame et al. 1987; Whyte 1996). For
only a few of these disorders is the pathogenesis estab-phase and a matrix phase that together are constantly
being degraded and then reformed throughout the skele- lished; the best understood are the osteopetroses, in
which histopathological studies incriminate a failureton. This process of bone breakdown and bone forma-
tion, called remodeling, is mediated by speciﬁc cell types of osteoclast-medicated resorption of skeletal tissue
(Whyte 1992). Primary spongiosa, the calciﬁed cartilage(osteoclasts and osteoblasts, respectively) that function
in health in a highly coordinated fashion. Development that is deposited during endochondral bone formation
at growth plates, is not remodeled away by osteoclastsof the adult skeleton is more complicated, involving
growth and modeling (shaping) of individual bones and can be seen encased within trabecular bone on mi-
croscopic examination (Whyte 1992). Pycnodysostosis,while remodeling is lifelong (Marks and Hermey 1996).
the disorder that some speculate affected the French im-
pressionist painter Henri de Toulouse-Lautrec (1864–Dense Bones
1901), results from cathepsin K deﬁciency (Gelb et al.
In some individuals, the growth, modeling, and/or re- 1996). A patient with craniometaphyseal dysplasia has
modeling of the skeleton are disturbed in such a way been reported to have low levels of a hydrogen-ion pump
that skeletal mass is increased. Dense bones may occur in osteoclasts (Yamamoto et al. 1993). The pathogenesis
because there is excessive formation and/or defective of other heritable disorders that cause dense bone is
degradation of osseous tissue. The term osteosclerosis more nebulous.
refers to increased density of trabecular (spongy) bone,
whereas hyperostosis refers to thickening of cortical Molecular Investigation of Dense-Bone Diseases
(compact) bone from deposition of osseous tissue along
Molecular studies have revealed the etiology of justsubperiosteal and/or endosteal surfaces. High bone mass
two diseases that cause dense bones in humans. Amongcan result from osteosclerosis and/or hyperostosis oc-
the at least eight true forms of osteopetrosis in mancurring focally or throughout the skeleton (Frame et al.
(Whyte 1992), only the autosomal recessive syndrome1987).
known as osteopetrosis/renal tubular acidosis/cerebralTypically, metabolic, neoplastic, hematologic, or nu-
calciﬁcation is delineated at the gene level. In this inborntritional disturbances are the etiology of dense bones.
error of metabolism, a variety of defects in the carbonicOccasionally, however, heritable conditions are the ex-
anhydrase II isoenzyme gene have been identiﬁed (Slyplanation. Although individually rare, there are §20
and Hu 1995). In fact, the chromosomal locations ofwell-recognized genetic causes of increased skeletal mass
other types of osteopetrosis (some autosomal dominant,(Frame et al. 1987; Whyte 1996). Furthermore, new
some autosomal recessive) remain unknown (Whytegenetic disorders featuring dense bones continue to ap-
1992). Recently, pycnodysostosis became the second ofpear in the literature, and this list of conditions will
the dense-bone diseases to be understood at the molecu-continue to grow.
lar level, when mutations were discovered in the cathep-
sin K gene (Gelb 1996).
In this issue of the Journal, Johnson et al. (1997)Received April 15, 1997; accepted for publication April 17, 1997.
describe a kindred in which high bone mass has beenAddress for correspondence and reprints: Dr. Michael P. Whyte,
Barnes-Jewish Hospital, 216 South Kingshighway, St. Louis, MO inherited as an autosomal dominant trait. Because high
63110. bone mass affects young adults as well as elderly family
This article represents the opinion of the author and has not been members, it is apparent that peak bone mass is in-
peer reviewed.
creased. Nevertheless, affected individuals appear to be 1997 by The American Society of Human Genetics. All rights reserved.
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endosteal surfaces (I anticipate that the radiological and ‘‘experiments of nature’’ that should disclose additional
approaches to low-bone-mass problems.perhaps histopathological studies of bone will be de-
picted in detail elsewhere). Perhaps this reﬂects a failure
of endosteal bone resorption, rather than hyperostosis Genetic Determinants of Bone Mass
(Frame et al. 1987; Resnick and Niwayama 1995).
Assays of biochemical markers that reﬂect skeletal turn- As Johnson et al. discuss in their report, family and
twin studies support an important genetic effect on peakover, however, suggest that this disorder is associated
with a normal rate of bone remodeling. I wonder bone mass (Sambrook et al. 1996). Studies using bio-
chemical markers of skeletal turnover suggest that thewhether this kindred has the so-called Worth type of
endosteal hyperostosis (Ade`s et al. 1994). Importantly, genetic inﬂuence on bone-mineral density is mediated
through regulation of bone remodeling. It is unclear,Johnson et al. report mapping studies that provide
strong evidence that the gene responsible for the high however, whether a genetic effect exists on rates of bone
loss with aging or after menopause. Studies of the herita-bone mass in this kindred is located on chromosome
11q12-13, which is of interest because this is the region bility of bone density suggest that Ç60%–80% of the
adult peak skeletal mass is genetically predeterminedwhere the phenotype known as osteoporosis pseudogli-
oma syndrome recently has been localized (Gong et al. (Sambrook et al. 1996). Some investigators report that
the gene that encodes the vitamin D receptor (VDR)1996).
may be a critical factor (Fleet et al. 1995). Certain poly-
morphisms in the VDR gene have been associated withWhy Study Dense Bones?
low bone-mineral density, in studies of some but not all
populations (Fleet et al. 1995; Looney et al. 1995). ThisAlthough genetic disorders that cause dense bones are
rare and some are mere radiological curiosities (Frame is a controversial topic in the ﬁeld of osteoporosis re-
search (Van Leeuwen et al. 1996). Understandably, at-et al. 1987; Resnick and Niwayama 1995; Whyte 1996),
searching for their molecular explanations is a worth- tention is now also being directed to identify other genes
that might be associated with familial osteoporoses.while quest. Osteoporosis, the converse clinical prob-
lem, is a major health concern in the United States and
elsewhere (Ray et al. 1997). In this condition, the min- Mapping Bone-Density Genes
eral:matrix ratio of bone tissue is essentially normal, but
there is insufﬁcient trabecular and/or cortical bone mass Currently, efforts are underway to identify suitable
kindreds or families in whom genomewide searches mayto meet the body’s structural requirements. In fact, os-
teoporosis is estimated to affect 10 million individuals disclose genes that are important in conditioning skeletal
mass (Spotila et al. 1991, 1996). Elucidation of the mo-in the United States. Most are women who have the
most prevalent type—postmenopausal osteoporosis. In lecular basis of osteogenesis imperfecta, a considerable
variety of mutations in the genes that encode the prothe United States, osteoporosis is a factor in an estimated
300,000 hip fractures/year and is a signiﬁcant cause of a1(I) and pro a2(I) chains that constitute the type I
collagen heterotrimer, has revealed the etiology of thismorbidity and mortality, especially for the elderly. The
cost associated with osteoporotic fractures recently has relatively rare form of familial osteoporosis (Byers
1995). However, bone is a complex tissue, and muta-been estimated as having been $13.8 billion in 1995 in
the United States (Ray et al. 1997). tions in any of the bone-speciﬁc structural proteins in-
volved in mineralization and remodeling might be in-Estrogen-replacement therapy can help to preserve
skeletal mass in women at menopause and thereby can volved in additional forms of osteoporosis. Other
regulatory pathways, reﬂected by the strong genetic in-help to decrease their risk of osteoporotic fractures. In
addition, the bisphosphonate alendronate and synthetic ﬂuence on biochemical parameters of bone formations
and breakdown, could be defective (Sambrook et al.salmon calcitonin are FDA-approved drugs for post-
menopausal osteoporosis and also act principally by 1996).
blocking bone resorption. Sodium ﬂuoride continues to
be investigated (Marcus et al. 1996). However, newer Conclusion
drugs that can safely and substantially increase skeletal
mass with good quality bone are needed. With the ad- Families with heritable disorders that cause dense
bones are one of nature’s windows on genetic factorsvancing age of the baby boomer population in the
United States, the problem of osteoporosis and fracture that condition skeletal mass. The report by Johnson et
al. is welcome progress from this resource. Molecularwill continue to grow (Ray et al. 1997). Hence, im-
proved understanding of the factors that condition peak studies should be matched by equally intensive investiga-
tion of the clinical, radiographic, histopathological, andskeletal mass or that regulate bone remodeling are cru-
cial. Heritable disorders that cause high bone mass are biochemical nature of these conditions, so that the mech-
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